| Identification | Back Directory | [Name]
BAR 501 | [CAS]
1632118-69-4 | [Synonyms]
BAR 501
CPDD0945
BAR 501; BAR-501
BAR501, 98%, a potent and selective agonist of GPBAR1
(3R,5S,6S,7S,8S,9S,10S,13R,14S,17R)-6-ethyl-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol | [Molecular Formula]
C26H46O3 | [MDL Number]
MFCD30738007 | [MOL File]
1632118-69-4.mol | [Molecular Weight]
406.64 |
| Chemical Properties | Back Directory | [Boiling point ]
527.6±25.0 °C(Predicted) | [density ]
1.047±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:65.5(Max Conc. mg/mL);161.07(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);49.18(Max Conc. mM)
Ethanol:34.33(Max Conc. mg/mL);84.42(Max Conc. mM) | [form ]
A crystalline solid | [pka]
14.82±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. | [in vivo]
Pretreating rats for 6 days with BAR501, 15 mg/kg, reduces basal portal pressure and blunts the vasoconstriction activity of norepinephrine. Pretreatment with BAR501 attenuates the hepatic vasomotor activity induced by shear stress and methoxamine. Administration of BAR501 exerts a direct vasodilatory activity in the CCl4 model. Treating mice with BAR501 at the dose of 15 mg/Kg reduces portal pressure and AST plasma levels. BAR501 attenuates endothelial dysfunction by regulating CSE expression/activity[1]. | [storage]
Store at -20°C | [References]
[1] Renga B, et al. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One. 2015 Nov 5;10(11):e0141082. DOI:10.1371/journal.pone.0141082 |
|
|